While most high-tech pioneers are using the information extracted from data mining to sell merchandise or make organizations operate more efficiently, Eric Lefkofsky is using data extraction and analysis to fine-tune subsequent cancer treatment in the search for a cure.According to Lefkofsky, “If you were to go into any of the nation’s cancer centers and ask which patients took Herceptin over two years and how they did, the center would need a grant and at least 90 days,” he noted. “That’s the sort of data that should flow freely between researchers, clinicians, and others.”
To that end, Lefkofsky has founded Tempus, a company dedicated to making an in-depth analysis of all available data from oncologists and best cancer treatment. Lefkofsky maintains that it is not enough to understand which treatments work for specific cancers, but that we must explore why they work as effectively as they do.“In order to treat cancer successfully, doctors need data—but they need data about several things,” said Lefkofsky, “this is what is missing from today’s medical research system.”
Lefkofsky told the attendees of the Fortune Brainstorm Health conference in San Diego, “There is no shortage of patient data out there, but there is a lack of sources that combine genomic information with therapeutic data.” He formed Tempus to gather and analyze both molecular data, such as DNA and RNA, and therapeutic outcome response data, such as detailed analysis of the rate of success of specific treatments amoung specific populations.Were different outcomes the result of specific factors? Race?Age?Gender?Ethnicity? Medical conditions?Environment?Lifestyle?Lefkofsky started Tempus when his wife was diagnosed with breast cancer. At that time, he was shocked to learn that business employees get better data and feedback than oncologists. He maintains that oncologists do not have trustworthy information about the reliability of particular treatments in precise groups of individuals.
Oncotarget is a multidisciplinary peer-reviewed open-access medical journal that publishes papers online in a weekly issue. The term “oncotarget” represents all pathways, molecules and cellular functions common in cancer and aging, lymphocytes and neurons, cancer cells and microbes, neurodegeneration and atherosclerosis. Oncotarget, which is published by Impact Journals, was founded in 2010. Its editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov. Members of the editorial board include Carlo M. Croce, the former editor-in-chief of Cancer Research and the Nobel Prize winner, Andrew Schally among many others. Oncotarget has produced four notable members. They are, Michael N. Hall, Bert Vogelstein, Stephen J. Elledge and Alexander Varshavsky who won the highly coveted Breakthrough Prize.
The journal’s increasing popularity has been brought about by educational, constructive,, insightful and multiple-review, which helps authors to boost the impact of their research. Their mission is to increase the availability of scientific research to a wider audience. They strive to utilize insightful review to achieve maximum impact of research and allow faster sharing of exceptional discoveries. The journal intends to break the barrier between specialties and connect diverse fields of biomedical science, while promoting applications of basic clinical science to find cures for diseases. Oncotarget accept papers beyond oncology. They cover broad topics, including pharmacology, cardiology, neuroscience, endocrinology, metabolism, immunology and microbiology, autophagy and cell death, and chromosome among others. Check Oncotarget in dovepress.com.
Authors are required to describe their results accurately and include an objective discussion of their original work. They may be requested to provide raw data and be ready to share the information with the public. They are also not required to submit research papers that had already been published in another journal. Editors evaluate papers strictly based on their scientific merit regardless of authors’ race, gender, citizenship or sexual orientation. Editors adhere to confidentiality of the manuscripts and do not use unpublished content for their personal use. They ensure that accepted papers are reviewed by at least two experts in the field of study before publishing. Only qualified reviewers are allowed to review manuscripts, which they are not allowed to discuss with unauthorized members. Reviews help authors to improve their work. However, personal criticism is not allowed.